703 related articles for article (PubMed ID: 16698684)
21. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
[TBL] [Abstract][Full Text] [Related]
22. Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.
Tran CA; Burton L; Russom D; Wagner JR; Jensen MC; Forman SJ; DiGiusto DL
J Immunother; 2007 Sep; 30(6):644-54. PubMed ID: 17667528
[TBL] [Abstract][Full Text] [Related]
23. Adoptive cellular immunotherapy with CD19-specific T cells.
Rössig C; Pscherer S; Landmeier S; Altvater B; Jürgens H; Vormoor J
Klin Padiatr; 2005; 217(6):351-6. PubMed ID: 16307422
[TBL] [Abstract][Full Text] [Related]
24. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2.
Mogi S; Ebata T; Setoguchi Y; Fujime M; Heike Y; Kohsaka T; Yagita H; Okumura K; Azuma M
Clin Cancer Res; 1998 Mar; 4(3):713-20. PubMed ID: 9533541
[TBL] [Abstract][Full Text] [Related]
25. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.
Li J; Mookerjee B; Wagner J
J Immunother; 2008 Jan; 31(1):81-8. PubMed ID: 18157015
[TBL] [Abstract][Full Text] [Related]
26. Ex vivo expansion of natural killer cells for clinical applications.
Klingemann HG; Martinson J
Cytotherapy; 2004; 6(1):15-22. PubMed ID: 14985163
[TBL] [Abstract][Full Text] [Related]
27. Targeting CD19 with genetically modified EBV-specific human T lymphocytes.
Roessig C; Scherer SP; Baer A; Vormoor J; Rooney CM; Brenner MK; Juergens H
Ann Hematol; 2002; 81 Suppl 2():S42-3. PubMed ID: 12611072
[TBL] [Abstract][Full Text] [Related]
28. [Isolation and expansion of glioma-infiltrating lymphocytes in vitro: an analysis of their surface phenotypes and antitumor activities].
Sawamura Y
Hokkaido Igaku Zasshi; 1991 Nov; 66(6):868-78. PubMed ID: 1783372
[TBL] [Abstract][Full Text] [Related]
29. Generation of Ag-specific cytotoxic T lymphocytes by DC transfected with in vitro transcribed influenza virus matrix protein (M1) mRNA.
Osman Y; Narita M; Ayres F; Takahashi M; Alldawi L; Tatsuo F; Toba K; Hirohashi T; Aizawa Y
Cytotherapy; 2003; 5(2):161-8. PubMed ID: 12745578
[TBL] [Abstract][Full Text] [Related]
30. Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function.
Landmeier S; Altvater B; Pscherer S; Eing BR; Kuehn J; Rooney CM; Juergens H; Rossig C
Cancer Res; 2007 Sep; 67(17):8335-43. PubMed ID: 17804749
[TBL] [Abstract][Full Text] [Related]
31. Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy.
Meehan KR; Wu J; Webber SM; Barber A; Szczepiorkowski ZM; Sentman C
Cytotherapy; 2008; 10(1):30-7. PubMed ID: 18202972
[TBL] [Abstract][Full Text] [Related]
32. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
33. Blood donor derived dendritic cells and cytotoxic T cells for specific fusion-gene adoptive immunotherapy.
Gallagher RC; Waterfall M; Samuel K; Turner ML
Vox Sang; 2007 May; 92(4):351-60. PubMed ID: 17456159
[TBL] [Abstract][Full Text] [Related]
34. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
35. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
36. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
37. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
[TBL] [Abstract][Full Text] [Related]
38. Characterization of human cytotoxic lymphocytes directed against cells infected with typhus group rickettsiae: evidence for lymphokine activation of effectors.
Carl M; Dasch GA
J Immunol; 1986 Apr; 136(7):2654-61. PubMed ID: 3081648
[TBL] [Abstract][Full Text] [Related]
39. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
40. [In vitro killing effect of mutant thymidine kinase mediated by lentiviral vector on T lymphocytes].
Xu KL; Pan XY; Yang YJ; Lu QX; Li ZY; He XP
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):678-81. PubMed ID: 16620557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]